Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration01:23

Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration

141
Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s...
141
Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship01:14

Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship

124
For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...
124
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

2.3K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
2.3K
Hazard Ratio01:12

Hazard Ratio

756
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
756
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

5.4K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
5.4K
Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

236
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
236

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

BMS - Consensus statement.

Post reproductive health·2018
Same author

Medical student experience in surgery influences their career choices: a systematic review of the literature.

Journal of surgical education·2014
Same author

Sexual function in women with anal incontinence using a new instrument: the PISQ-IR.

International urogynecology journal·2014
Same author

The PISQ-IR: considerations in scale scoring and development.

International urogynecology journal·2013
Same author

Breast cancer patient stories project.

Menopause international·2012
Same author

Alternative and complementary therapies for the menopause.

Menopause international·2012
Same journal

Estrogen and the brain: does estrogen treatment improve cognitive function?

Menopause international·2016
Same journal

Vitamin D supplements for the prevention of osteoporosis judged 'inappropriate'.

Menopause international·2014
Same journal

Estradiol associated with lower thrombotic risk than conjugated equine estrogens when used as oral HRT.

Menopause international·2014
Same journal

Stand by your man: the importance of the female in male sexual problems.

Menopause international·2013
Same journal

The effect of hormones on the lower urinary tract.

Menopause international·2013
Same journal

Extended follow-up of WHI finds ‘complex’ pattern of risk and benefit.

Menopause international·2013
See all related articles

Related Experiment Video

Updated: May 4, 2026

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

1.7K

Should HRT be duration limited?

Joan Pitkin1

  • 1North West London Hospitals, NHS Trust, Harrow, UK.

Menopause International
|December 17, 2013
PubMed
Summary
This summary is machine-generated.

Hormone Replacement Therapy (HRT) remains controversial despite new evidence supporting its safety. This review examines HRT risks, benefits, and long-term outcomes for women, especially those with Premature Ovarian Insufficiency (POI).

Keywords:
British Menopause SocietyHormone replacement therapyInternational Menopause SocietyNational Osteoporosis Societyconsensus statementduration of therapypremature ovarian failurepremature ovarian insufficiencysafety data

More Related Videos

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

11.7K
Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives
08:46

Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives

Published on: September 16, 2021

6.0K

Related Experiment Videos

Last Updated: May 4, 2026

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

1.7K
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

11.7K
Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives
08:46

Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives

Published on: September 16, 2021

6.0K

Area of Science:

  • Reproductive endocrinology and women's health.
  • Menopause management and hormone therapy.

Background:

  • Hormone Replacement Therapy (HRT) faces negative public perception and media portrayal.
  • Concerns persist despite re-analyzed data and consensus statements supporting HRT.
  • General Practitioners often limit HRT duration or discontinue it prematurely.

Purpose of the Study:

  • To review current evidence on the safety and efficacy of HRT.
  • To present new data on the long-term consequences of not treating Premature Ovarian Insufficiency (POI).
  • To explore the implications of HRT for the older female workforce and propose management strategies.

Main Methods:

  • Comprehensive review of existing and novel research on HRT safety.
  • Analysis of long-term health outcomes in women with untreated POI.
  • Exploration of workforce participation and health considerations for aging women.

Main Results:

  • Re-evaluation of previous data and new studies indicate a more favorable safety profile for HRT than commonly perceived.
  • Untreated POI is associated with significant long-term adverse health consequences.
  • Evidence supports individualized HRT management plans.

Conclusions:

  • A balanced, evidence-based approach to HRT is warranted, moving beyond outdated perceptions.
  • Individualized HRT prescriptions should consider patient history, risks, and benefits.
  • Addressing POI and supporting older women in the workforce requires informed HRT strategies.